• Italian Adaptation and Validation of Functional and Behavioural Scales for Subjective Cognitive Decline, Mild Cognitive Impairment and Mild Dementia.

  NCT06701630

  RecruitingObservationalUpdated Feb 13, 2025
• ItaliaN Study With Tailored Multidomain Interventions to Prevent Functional and Cognitive Decline in Community-dwelling Older Adults

  NCT06248723

  RecruitingInterventionalNot ApplicableUpdated Jul 29, 2025
• TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics.

  NCT07399418

  RecruitingObservationalUpdated Feb 17, 2026
• Biomarkers in Alzheimer's and Parkinson's Diseases for IA

  NCT07651085

  Active, not recruitingObservationalUpdated Jun 16, 2026
• The Signature of Alzheimer's Disease in Subjective Cognitive Decline

  NCT07402161

  RecruitingObservationalUpdated Feb 11, 2026
• Advances in Neuropsychological Diagnostics

  NCT05794061

  RecruitingObservationalUpdated Sep 17, 2025

ClinicalTrials.gov ID

NCT07533084

Lead Sponsor

Neuromed IRCCSOTHER

Overall Status

Not yet recruiting

Study Type

Observational

Enrollment

265Estimated

Last Update Posted

Jun 11, 2026Actual

Start Date

Sep 2026Estimated

Primary Completion Date

Nov 27, 2027Estimated

Completion Date

Nov 27, 2027Estimated

Official Title

Italian Validation of the Dynamic Neurocognitive Adaptation (dNA) Scale and Its Correlation With Neurocognitive Variables

Brief Summary

The goal of this experimental multicentric intervention study is to validate, in Italian, the dynamic Neurocognitive Adaptation (dNA) Scale, which has already been validated in English, among a healthy elderly population (aged 65 and older) residing in Italy and patients with dementia or Alzheimer's Disease. dNA is a questionnaire designed to assess both current and past levels of engagement in physical, cognitive, creative, and social activities.

The study aims to recruit a total of 265 participants with mild cognitive impairment, subjective memory complaints, or dementia. These participants will be distributed among the 8 recruitment centers. Neuropsychological data, subjective measures, and MRI data will be collected and analyzed to address the following research questions: 1) Is there a positive correlation between scores on the dNA Scale and cognitive efficiency, as reflected in neuropsychological measures, such as episodic memory and executive functions? 2) Is there a correlation between dNA scores and improved functional connectivity within neural networks, such as the Default Network (DN)?

Participants recruited at the participating clinical centers will undergo:

• A clinical interview, during which demographic and medical history information will be collected. The dNA Scale will be administered, along with a questionnaire assessing adherence to dietary habits typical of a Mediterranean diet (14-Item Mediterranean Diet Adherence Screener; MEDAS).
• A neuropsychological assessment, aimed at evaluating general cognitive function with a particular focus on episodic memory and executive functions. The following tests will be administered: Mini-Mental State Examination (MMSE) or, alternatively, Montreal Cognitive Assessment (MoCA); Rey Auditory Verbal Learning Test (RAVLT); Trial Making Test (TMT) Form B; Digit Span Forward and Backward (WAIS or WAIS-III); and the Stroop Test.
• Self-report questionnaires designed to assess depressive symptoms using the Geriatric Depression Scale (GDS) and anxiety symptoms using the Geriatric Anxiety Scale (GAS) (or alternatively the State-Trait Anxiety Inventory, STAI). Finally, the Cognitive Reserve Index Questionnaire will be administered to estimate Cognitive Reserve (CRIq).
• Where available, MRI data previously acquired for clinical or diagnostic purposes will be included in the study and analyzed by the principal investigator.

Detailed Description

This study aims to validate the instrument known as the dynamic Neurocognitive Adaptation Scale (dNA), derived from the identical scale previously validated in English on a sample of 815 subjects residing in the United States. All the clinical centers involved will recruit approximately 265 subjects, administer the aforementioned scale, and collect demographic and medical history information. This information will be necessary and sufficient for the first part (Stage #1) of the instrument's validation. Actually, according to the literature, the number of participants required to validate a scale with 20 items- which has already been validated in another language-is approximately 250 participants. Other studies suggest a minimum of 200 subjects to test cross-cultural consistency and reliability. The dNA scale, already validated in English, reports a KM O index greater than .80 (i.e., good), a specific index (Kaiser-Meyer-Olkin) for confirming the appropriateness of the sample. Specifically, for the CFA, this sample size calculation accounts for the need to detect a medium effect size, expressed in terms of Root Mean Square Error of Approximation (RMSEA), with an expected value of 0.05, a statistical power (1-β) of 0.80, and a significance level α of 0.05. Taking potential dropouts into account, approximately 265 subjects will be recruited to ensure the minimum sample size required for statistical power, and this number will be verified experimentally during the validation phase using the KMO index.

Each of the 8 participating centers, depending on their recruitment capacity, will enroll approximately at least 30 participants. The majority of the final sample (i.e., 265 participants) will consist of healthy older adults (HC), while a smaller percentage will include subjects with subjective memory complaints (SMC), mild cognitive impairment (MCI), or Alzheimer's disease (AD).

The first phase (Stage #1) will be followed by a second part (Stage #2) focused on exploring the correlation between the dNA score and neuropsychological variables (particularly those related to memory and executive functions), with the aim of investigating a measure of adaptation that is primarily cognitive in nature. This adaptation will provide a measure of cognitive efficiency, commonly referred to in the literature as cognitive reserve or resilience. In this phase, adherence to a Mediterranean-style diet (i.e., the Mediterranean diet, assessed via a specific questionnaire) will also be explored as a protective factor against general inflammatory processes and cognitive decline associated with Alzheimer's disease (AD).

During the third phase (Stage #3), a measure of neural adaptation will be explored, collecting data on neural efficiency. In the literature, this is a form of resilience or adaptation often described as neural reserve. This component will be explored using structural magnetic resonance imaging (MRI) and functional magnetic resonance imaging (fMRI).

Demographic information, medical history, dietary habits, and neuropsychological data collected by the participating centers will be compiled and managed at the Universities of Chieti and Foggia, under the coordination and responsibility of Professor Michela Balsamo (CH) and Professor Leonardo Carlucci (FG), respectively, both of whom have established expertise in statistics and psychometrics, particularly in the validation of instruments within the field of psychology. The two universities will carry out the data analysis phase aimed at validating the scale (Stage #1), also accounting for key demographic variables (age, sex, education level).

For the primary analyses, principal component analysis (PCA) and exploratory factor analysis (EFA) will be conducted to identify the underlying structure of the dNA instrument and determine the number of components, forming the basis for a subsequent confirmatory factor analysis (CFA) in the validation sample. Descriptive statistics will be used to characterize the study sample. Prior to EFA, sample adequacy (KMO) and variance homogeneity (Bartlett's test) will be assessed, while internal consistency will be evaluated using Cronbach's alpha and inter-item correlations. CFA will be performed using a structural equation modeling (SEM) approach with maximum likelihood estimation to test the hypothesized factor structure. Model fit indices will be calculated, including chi-square (p-value > 0.05), root mean square error of approximation (RMSEA; cutoff ≤ 0.06), normed fit index (NFI), comparative fit index (CFI; cutoff ≥ 0.90), Tucker-Lewis index (TLI; cut-off ≥ 0.95), and standardized root mean square residual (SRMR; cut-off ≤ 0.08). Finally, the coefficient of determination (R²) will be calculated to assess the proportion of variance explained between factors.

Subsequently, during the second phase (Stage #2), dNA scale scores will be analyzed in relation to the aforementioned dietary habits and neuropsychological variables, particularly memory and executive functions. Correlation analyses will be conducted across the scale domains (cognitive, physical, creative, and social) using distance correlations. The domains will also be examined across the seven time periods considered in the dNA scale (i.e., childhood, adolescence, young adulthood, adulthood, midlife, senior age, and old age) using repeated-measures ANOVA (RM-ANOVA) with Greenhouse-Geisser sphericity corrections. Within-subject effects of time, as well as interactions between time, gender, and education level, will be assessed. Planned contrasts will be conducted within domains for specific pairwise time comparisons and significant interactions, followed by post hoc comparisons using the Bonferroni-Holm correction. Additionally, correlations between the scale and adherence to a Mediterranean diet, as well as performance on cognitive tests assessing memory and executive functions, will be evaluated. Moderation analyses will test whether higher dNA scores may moderate negative effects on neuropsychological outcomes (i.e., lower scores in memory and executive functions) and neurophysiological measures (i.e., poor anticorrelation between the default mode network and task-positive networks such as DAN/FPCN).

All participating clinical centers will collect demographic, medical history, dietary habit, neuropsychological, and, where available, imaging data (MRI, fMRI). These data will be used in the third phase (Stage #3), which will be focused on identifying the neural correlates of adaptation (i.e., neural efficiency) during aging. Imaging data collected by the participating clinical centers will be transferred to the University of Padua, which will oversee data receipt and analysis under the coordination and responsibility of Dr. Marco Marino, whose research focuses on the neural substrates underlying neurocognitive adaptation during aging.

In this phase, both structural (e.g., volumetric and cortical thickness) and functional (e.g., resting-state fMRI) analyses will be performed. Regions of interest (ROIs) will be defined based on prior literature and mapped from standard (MNI) space to individual brain space. Spherical ROIs will be created, and their activity will be summarized using principal component analysis. Functional connectivity maps will be generated by correlating ROI time series with whole-brain activity and then normalized to MNI space for group-level analyses, with statistical significance corrected for multiple comparisons (FDR). Graph theory analysis will be applied to the functional network generated with AAL Atlas (Tzourio-Mazoyer et al., 2002) using the GRETNA software (Wang et al., 2015). Five global indices derived from the graph analysis will be analyzed and correlated with the results of the dNA scale. The effects of diagnosis and functional connectivity on cognitive outcomes (memory scores and other neuropsychological tests) will be examined using ANCOVA and regression models, including interaction effects and group-specific analyses. Additional regression analyses will assess differences in the relationship between cognitive performance and connectivity metrics. Age, handedness, and education will be included as covariates. This phase will receive scientific support from the University of Leuven (Dr. Dante Mantini) and the Cleveland Clinic (Dr. Filippo Cieri); however, these institutions and their respective researchers will not have access to the data.

• Active Aging Individuals Aged 65 and Over
• Aging
• Mild Cognitive Impairment (MCI)
• Dementia
• Dementia Alzheimer Type
• Subjective Memory Complaints
• Probable Alzheimer's Disease

Ages Eligible for Study

Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria (Stage #1):

• Individuals aged ≥ 65 years residing in Italy;
• Cognitively healthy individuals (HC);
• Individuals with subjective memory complaints (SMC);
• Individuals with mild cognitive impairment (MCI);
• Individuals with probable Alzheimer's disease (AD).

Inclusion criteria (Stage #2 & Stage #3):

• Individuals aged ≥ 65 years residing in Italy;
• Cognitively healthy individuals (HC);
• Individuals with subjective memory complaints (SMC);
• Individuals with mild cognitive impairment (MCI);
• Individuals with probable Alzheimer's disease (AD);
• Individuals with Alzheimer's disease or other forms of dementia;
• Individuals suffering from mental disorders clinically diagnosed.

Cognitively healthy individuals (HC):

• MMSE score ≥24, or alternatively MoCA score ≥26;
• No diagnosis of depression, MCI or any form of dementia;
• Episodic memory performance within the normal range (Wechsler Memory Scale Logical Memory II ≥9 for 16 years of schooling or more; ≥5 for 8-15 years of schooling, ≥3 for 0-7 years of schooling; or alternatively for Prose Memory Test with scores ≥9 for ≥16 years of schooling → ≥5 items in immediate or delayed recall; ≥5 for 8-15 years of schooling → ≥3-4 items in immediate or delayed recall; ≥3 for 0-7 years of schooling → ≥2 items in immediate or delayed recall)

Individuals with Subjective Memory Complaints (SMC):

• MMSE score ≥24, or alternatively MoCA score ≥26;
• A significant memory impairment, reported by the subject, a family member, or the clinician;
• No diagnosis of depression, MCI or any form of dementia;
• Episodic memory performance within the normal range on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling (≥9 for 16+ years of schooling, ≥5 for 8-15 years of schooling, ≥3 for 0-7 years of schooling) or, alternatively, on the Prose Memory Test (with scores ≥9 for ≥16 years of schooling → ≥5 items in immediate or delayed recall; ≥5 for 8-15 years of schooling → ≥3-4 items in immediate or delayed recall; ≥3 for 0-7 years of schooling → ≥2 items in immediate or delayed recall)

Individuals with Mild Cognitive Impairment (MCI):

• MMSE score between 19 and 23 inclusive (alternatively MoCA);
• A decline in memory reported by the subject, a family member, or the clinician;
• No diagnosis of depression or affected by any form of dementia, with preserved ability in activities of daily living;
• Objective episodic memory loss on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling.

Individuals with probable Alzheimer's disease (AD):

• Insidious onset with atypical course: some criteria for probable AD are met, but the onset of symptoms may have been sudden, or there is a lack of objective evidence of progressive cognitive decline;
• Mixed etiology presentation: All criteria for probable AD are met, with concomitant cerebrovascular disorders, or the presence of features typical of another dementia or the evidence of other neurological disorders or non-neurological comorbidities;
• A decline in performance compared to the previous level of functioning is evident, as also described by a caregiver (often a family member)
• Onset with memory disturbances, defined as difficulty learning new information or recalling it;
• Onset with non-mnemonic symptoms (language symptoms, particularly difficulty finding the correct words; visuospatial symptoms: perceptual deficits characterized by failure to recognize objects, people, or written words; executive symptoms: difficulties with reasoning and critical thinking);
• MMSE score < 23 (alternatively MoCA < 25);
• Objective episodic memory loss on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling.

Exclusion criteria (Stage #1):

• Individuals aged < 65 years;
• Individuals not residing in Italy;
• Individuals with depression or other psychiatric disorders;
• Individuals with forms of dementia other than Alzheimer's disease.

Observational Model

Cohort

Time Perspective

Cross-Sectional

Lead Sponsor

Neuromed IRCCSOTHER

Collaborators

Istituto ricerca carattere Scientifico Fatebenefratelli BresciaUNKNOWN

IRCCS National Neurological Institute "C. Mondino" FoundationOTHER

Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER

IRCCS San Camillo, Venezia, ItalyOTHER

IRCCS Ospedale San RaffaeleOTHER

Campus Bio-Medico UniversityOTHER

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER

Università degli Studi 'G. d'Annunzio' Chieti e PescaraOTHER

University of FoggiaOTHER

University of PadovaOTHER

direzione.scientifica@hsanmartino.it+390105558722

filippi.massimo@hsr.it+390226433958

alfredo.costa@unipv.it+390382380343

v.dilazzaro@policlinicocampus.it+39 06 22541 1220

giorgio.arcara@hsancamillo.it+390412207594